Clinical Trial

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Study acronym: PSI-PD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
Protocol Amendment History 5 changes
critical Recruitment opened 2026-07-21
notable Primary completion pushed: 2030-06 -> 2030-07 2026-07-21
minor Completion pushed: 2030-06 -> 2030-07 2026-07-21
notable Primary completion pushed: 2030-05 -> 2030-06 2026-06-30
minor Completion pushed: 2030-05 -> 2030-06 2026-06-30
Trial Details
NCT Number NCT07610369
Lead Sponsor Yale University
Collaborators: Michael J. Fox Foundation for Parkinson's Research
Conditions Depression, Parkinson's Disease (PD)
Enrollment 40 participants
Start Date 2026-07
Primary Completion 2030-07 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-20